FDA Review of RSV Infant Shots Alarms Treasure Coast Pediatricians

The Food and Drug Administration is reviewing the safety of monoclonal antibody shots that protect infants against respiratory syncytial virus, alarming pediatric specialists who say the products have already sharply reduced infant hospitalizations.

RSV is the leading cause of hospitalization for babies in their first year of life, according to the Centers for Disease Control and Prevention. The two laboratory-made antibody shots — manufactured by Sanofi and Merck — are approximately 80 percent effective at preventing infants from requiring intensive care due to RSV. More than half of U.S. infants had received one of the shots as of a CDC survey in February.

On the Treasure Coast, where St. Lucie County consistently records some of the highest infant hospitalization rates in Florida, pediatricians at facilities including Cleveland Clinic Martin Health have administered the RSV antibody shots since their introduction. Parents of newborns in Martin, St. Lucie and Indian River counties seeking the shots this coming RSV season — typically peaking between October and March — could face restricted access if the FDA review leads to new limits on distribution or prescribing guidance.

The FDA announced the review in December but has not disclosed when it will be completed. Dr. Sean O'Leary, who chairs the American Academy of Pediatrics's infectious disease committee, said the products "were already thoroughly reviewed for safety, including by the FDA," and called concerns raised by the review unfounded. Dr. Yvonne Maldonado, a pediatric infectious disease specialist at Stanford University, described RSV's effects on infants as severe, noting some babies end up on ventilators and develop chronic lung disease or asthma.

Others have welcomed the review. Brian Hooker, chief medical officer for the Children's Health Defense, cited reported adverse reactions — including fevers, seizures and some deaths — as justification. Sanofi and Merck both said no deaths in their clinical trials were linked to the immunization and that the FDA reached the same conclusion in reviewing their data.

The review comes as Health and Human Services Secretary Robert F. Kennedy Jr. faces a federal court order — issued by a judge in Boston — temporarily blocking his administration's cuts to federally backed childhood vaccine programs. Kennedy's broader vaccine policies remain under legal challenge.

Separately, attorney Aaron Siri has petitioned Kennedy to add more than 300 conditions eligible for compensation under the federal Vaccine Injury Compensation Program. Public health experts warn such an expansion could threaten the program's solvency and undermine the vaccine market by exposing manufacturers to greater legal liability.

The FDA has not set a timeline for concluding its RSV antibody review.

This article was generated with AI assistance using publicly available information. It was reviewed and approved by a human editor before publication. TC Sentinel uses AI writing tools in accordance with FTC guidelines.